Hit a Semaglutide Plateau? Why It Happens (and What It Means)

You were losing steadily on semaglutide, and then the scale stopped moving. It is one of the most discouraging moments in any weight-loss journey — and one of the most misunderstood. The honest, evidence-based answer is reassuring: for most people, a plateau is not a sign the drug stopped working or that you did something wrong. It is what the trial data predict, and it reflects how the body defends its weight. Here is what is actually happening, when to expect it, and how to tell a normal plateau from a real problem.

The short answer: plateaus are built into the curve

In the pivotal STEP 1 trial — 68 weeks of semaglutide 2.4 mg in adults with overweight or obesity — the average participant lost about 15% of body weight, but the weight curve did not fall in a straight line forever. It declined steadily for roughly the first 60 weeks and then flattened into a plateau, with weight holding roughly stable thereafter¹. The longer STEP 5 trial, which followed people for two full years, tells the same story: the bulk of weight loss accrued in the first year, and weight then stabilized and was largely maintained through year two rather than continuing to drop². The four-year SELECT analysis confirms the pattern at scale — weight loss continued for about the first 65 weeks, then plateaued and was sustained for the remainder of the study³.

In other words, a plateau is not the exception. It is the expected shape of the curve. The question is rarely "did the drug fail?" — it is "have I reached the weight my body and dose are going to settle at?"

Why your body pushes back — it is the condition, not a failure

The reason weight loss stalls is the same reason obesity is so hard to treat in the first place: the body actively defends a higher weight. As the Endocrine Society's scientific statement on obesity pathogenesis lays out, body weight is regulated around a biologically "defended" level by hormones and brain circuits that adjust hunger and energy use to resist change⁴. When you lose weight, those systems fight back — appetite-promoting signals rise and the body becomes more energy-efficient, a phenomenon documented vividly in the long-term follow-up of "The Biggest Loser" contestants, whose resting metabolism remained suppressed years after their weight loss⁵.

Semaglutide works by counteracting some of these appetite signals⁶. That is exactly why it produces meaningful loss in the first place — and also why the loss is finite. The drug shifts your defended weight downward to a new, lower level; once you reach that new equilibrium, the same regulatory biology that fought your weight loss now holds you steady there. A plateau, in this light, is your body finding its new set-point on the medication — not the medication quitting.

When plateaus typically show up

There is no single universal week, but the trial trajectories give a realistic frame:

• •Early "mini-stalls" during titration (first ~16–20 weeks): Weight can pause for a week or two as your dose steps up. These are usually just noise — water shifts, normal fluctuation — not a true plateau.
• •The real plateau (often around the 1-year mark): In STEP 1 the curve flattened near week 60¹; in SELECT, around week 65³. This is the big one — the point where most of the achievable loss at your dose has happened.
• •The maintenance phase (year two and beyond): STEP 5 shows weight holding roughly stable into year two². At this stage, maintaining the loss is itself a clinical success, even though the scale is no longer dropping.

Importantly, the appetite benefit does not vanish when the scale stalls. In STEP 5's two-year data, the reduction in appetite and control-of-eating benefit was still present at two years⁷ — the drug is still working; it has simply brought you to equilibrium.

How to tell a normal plateau from a real problem

Most plateaus need patience and a check-in, not panic. A few honest distinctions:

• •A genuine plateau is weight holding stable for several weeks after a long period of steady loss, especially if you have already reached a substantial loss and your maintenance dose. This is usually the expected endpoint of the curve, not a malfunction.
• •A stall during titration — before you have reached the 2.4 mg maintenance dose — often resolves as the dose climbs, since the full effect is meant to arrive after you reach maintenance, not during the ramp. (For how that ladder works, see our Wegovy dose escalation schedule.)
• •A worth-discussing plateau is one where you stalled well short of the kind of loss seen in the trials and have been at the maintenance dose for a sustained stretch. Trial averages are averages — some people respond less — and that is a conversation for your prescriber, not a reason to self-escalate the dose.

What actually helps (and what to be skeptical of)

Honestly, there is no proven trick to "break through" a biologically defended plateau on demand — and you should be wary of anyone selling one. What the evidence supports is sensible and unglamorous:

• •Protect your muscle. A meaningful share of weight lost on semaglutide is lean mass, which lowers the metabolic rate that burns calories. Prioritizing protein and resistance training helps preserve muscle and the metabolism that goes with it — we cover this in will semaglutide make you lose muscle?.
• •Reassess habits honestly. Appetite suppression can fade in subjective intensity over months even while the drug works; portions can quietly creep up. Revisiting what to eat on Wegovy and tracking intake can surface drift.
• •Reframe the goal. Once you have reached your plateau, the objective shifts from losing to not regaining — and that is where the data is genuinely encouraging, because staying on the drug holds the loss (see below).
• •Talk to your prescriber about whether your dose, timeline, and overall plan still fit. Do not change your own dose to chase the scale.

A plateau is not the same as the drug "stopping"

This is the crucial distinction, and it is good news. A plateau means you have reached an equilibrium while still on the medication — your loss is being held. That is completely different from stopping semaglutide, after which most people regain a substantial portion of the weight: in the STEP 1 extension, participants regained about two-thirds of their lost weight within a year of withdrawal⁸. We cover that fully in what happens when you stop semaglutide. The STEP 4 trial makes the mirror-image point: people who continued semaglutide maintained their loss, while those switched to placebo regained⁹. So hitting a plateau is not a reason to quit — quitting is what actually reverses the progress.

Obesity is increasingly understood and treated as a chronic condition requiring ongoing management rather than a problem you fix once and walk away from¹⁰. A plateau is simply what successful long-term management looks like: a lower, defended, held weight.

The honest bottom line

If your weight has stalled on semaglutide after months of steady loss, the most likely explanation is the most reassuring one — you have reached the plateau that the STEP 1, STEP 5, and SELECT trials all show is a normal, built-in feature of the weight curve, typically around the one-year mark¹²³. It reflects your body settling at a new defended set-point⁴, not the drug failing. Protect muscle, reassess habits, keep realistic expectations, and bring persistent or early stalls to your prescriber rather than self-escalating. And remember the real risk to your results is not a plateau — it is stopping⁸. For the full evidence picture, see Semaglutide: How It Works, Results & Side Effects, and if you are weighing providers, our best semaglutide providers guide ranks options on price and oversight.